These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10468294)

  • 1. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
    Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
    Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
    Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
    Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
    Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
    J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the care of the patient with malignant melanoma.
    Reintgen D; Balch CM; Kirkwood J; Ross M
    Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
    Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
    BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
    Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
    J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
    Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
    J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
    J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
    J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
    Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
    Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
    Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
    J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
    Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
    Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
    Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
    Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.